Immune Design Corp. (IMDZ) Sees Unusually-High Trading Volume
Immune Design Corp. (NASDAQ:IMDZ) saw unusually-strong trading volume on Thursday . Approximately 105,953 shares changed hands during mid-day trading, an increase of 86% from the previous session’s volume of 56,860 shares.The stock last traded at $6.56 and had previously closed at $6.62.
A number of equities analysts have recently commented on IMDZ shares. Wells Fargo & Co. restated a “buy” rating on shares of Immune Design Corp. in a report on Wednesday, May 11th. Leerink Swann reiterated a “buy” rating on shares of Immune Design Corp. in a report on Friday, June 10th. Zacks Investment Research downgraded Immune Design Corp. from a “buy” rating to a “hold” rating in a report on Friday, May 13th. Jefferies Group reiterated a “buy” rating and set a $17.00 target price (down from $20.00) on shares of Immune Design Corp. in a report on Wednesday, August 10th. Finally, Cowen and Company reiterated a “buy” rating on shares of Immune Design Corp. in a report on Wednesday, May 11th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $14.50.
The company’s market cap is $132.35 million. The company’s 50 day moving average is $7.32 and its 200 day moving average is $10.65.
Immune Design Corp. (NASDAQ:IMDZ) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by $0.03. Analysts predict that Immune Design Corp. will post ($2.70) earnings per share for the current year.
An institutional investor recently raised its position in Immune Design Corp. stock. Jennison Associates LLC raised its position in shares of Immune Design Corp. (NASDAQ:IMDZ) by 0.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 203,452 shares of the company’s stock after buying an additional 769 shares during the period. Jennison Associates LLC owned about 1.01% of Immune Design Corp. worth $4,085,000 at the end of the most recent reporting period.
Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo.